Watson Pharmaceuticals, Inc. a leading integrated global pharmaceutical company, confirmed that the United States District Court for the District of Nevada denied Duramed Pharmaceuticals, Inc.'s request for a preliminary injunction and request for a temporary restraining order preventing Watson's launch of generic Seasonique (levonorgestrel/ethinyl estradiol (0.15 mg/0.03 mg) and ethinyl estradiol (0.01 mg). The company is evaluating plans to launch the contraceptive product.

On March 25, 2011, Watson received a favourable decision from the United States Court of Appeals for the Federal Circuit that reversed and remanded for trial a March 31, 2010 summary judgement order from the United States District Court for the District of Nevada regarding United States Patent No. 7,320,969 (the '969 patent).

On January 22, 2008, Watson notified Teva Women's Health that Watson's ANDA contained a paragraph IV certification asserting that the '969 patent is invalid, unenforceable and/or not infringed.

Seasonique is indicated for the prevention of pregnancy. It is a registered trademark of Teva Women's Health, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company and is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.